Advances in regional chemotherapy of the liver

Expert Opinion on Drug Delivery

Volumn 8, Issue 8, 2011, Pages 1057-1069

  Dudeck, Oliver ^a   Ricke, Jens ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Colorectal liver metastases; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Isolated hepatic perfusion; Regional chemotherapy; Transarterial chemoembolization

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; COLLAGEN; DEGRADABLE STARCH MICROSPHERE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GELATIN SPONGE; GELFOAM; IODINATED POPPYSEED OIL; IRINOTECAN; MITOMYCIN C; MITOXANTRONE; OXALIPLATIN; POLYVINYL ALCOHOL; SORAFENIB; STARCH MICROSPHERE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL (TOPIC); COIL EMBOLIZATION; COLORECTAL CARCINOMA; CONSERVATIVE TREATMENT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG INFUSION; DRUG INSTILLATION; DRUG MEGADOSE; HEPATIC ARTERY INFUSION; HUMAN; INOPERABLE CANCER; INTERMETHOD COMPARISON; ISOLATED HEPATIC PERFUSION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER PERFUSION; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGIONAL CHEMOTHERAPY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS;

EID: 79960797179     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.574125     Document Type: Review

References (131)

1. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969-77
2. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984;2:498-504 (Pubitemid 14075984)
3. Wallace S, Carrasco CH, Charnsangavej C, et al. Hepatic artery infusion and chemoembolization in the management of liver metastases. Cardiovasc Intervent Radiol 1990;13:153-60 (Pubitemid 20269114)
4. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
5. Kim WR, Gores GJ, Benson JT, et al. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005;129:486-93 (Pubitemid 41096636)
6. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73
7. Ji SK, Cho YK, Ahn YS, et al. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization Korean. J Radiol 2008;9:534-40
8. Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007;18:365-76 (Pubitemid 46616707)
9. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25 (Pubitemid 44900485)
10. Ahrar K, Gupta S. Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. Surg Oncol Clin N Am 2003;12:105-26 (Pubitemid 36204983)
11. Johnson PJ, Kalayci C, Dobbs N, et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 1991;13:120-7
12. Goldberg JA, Kerr DJ, Blackie R, et al. Mitomycin C-loaded microcapsules in the treatment of colorectal liver metastases. Pharmacokinetics of regionally administered particulate chemotherapy. Cancer 1991;67:952-5
13. Yoon CJ, Chung JW, Park JH, et al. Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology 2003;229:126-31 (Pubitemid 37152114)
14. Lin DY, Liaw YF, Lee TY, et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial. Gastroenterology 1988;94:453-6
15. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-4
16. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61
17. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-83 (Pubitemid 28264682)
18. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC J Hepatol 1998;29:129-34 (Pubitemid 28307992)
19. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71 (Pubitemid 34454013)
20. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002;359:1734-9 (Pubitemid 34607087)
21. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42 (Pubitemid 36152543)
22. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36 (Pubitemid 43112690)
23. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12:1260-7 (Pubitemid 44194595)
24. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-81 (Pubitemid 46201723)
25. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the RECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52
26. Nicolini A, Martinetti L, Crespi S, et al. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:327-32
27. Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:541-51
28. Scartozzi M, Svegliati BG, Faloppi L, et al. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res 2010;29:164
29. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
30. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
31. Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008;49:523-9
32. Virmani S, Rhee TK, Ryu RK, et al. Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 2008;19:1483-9
33. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30
34. Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007;17:1025-34 (Pubitemid 46766884)
35. Lorenz M, Staib-Sebler E, Hochmuth K, et al. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol 2000;27:112-19
36. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet 2005;365:153-65 (Pubitemid 40091806)
37. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003;8:553-66 (Pubitemid 37467371)
38. Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med 2005;56:139-56 (Pubitemid 40299777)
39. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-75
40. Kemeny N, Garay CA, Gurtler J, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/ leucovorin compared with fluorouracil/ leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004;22:4753-61
41. Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008;12:iii-162
42. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006;24:3347-53 (Pubitemid 46638888)
43. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37 (Pubitemid 41095086)
44. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
45. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71
46. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523-9
47. Ochenduszko SL, Krzemieniecki K. Targeted therapy in advanced colorectal cancer: more data, more questions. Anticancer Drugs 2010;21:737-48
48. Tellez C, Benson AB III, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998;82:1250-9 (Pubitemid 28155386)
49. Vogl TJ, Gruber T, Balzer JO, et al. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009;250:281-9
50. Inoue H, Kobayashi H, Itoh Y, et al. Treatment of liver metastases by arterial injection of adriamycin/mitomycin C lipiodol suspension. Acta Radiol 1989;30:603-8 (Pubitemid 20130321)
51. Martinelli DJ, Wadler S, Bakal CW, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994;74:1706-12 (Pubitemid 24301823)
52. Lang EK, Brown CL Jr. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993;189:417-22 (Pubitemid 23321421)
53. Tancredi T, McCuskey PA, Kan Z, et al. Changes in rat liver microcirculation after experimental hepatic arterial embolization: comparison of different embolic agents. Radiology 1999;211:177-81 (Pubitemid 29161748)
54. Dudeck O, Zeile M, Wybranski C, et al. Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. Eur Radiol 2010;20:2699-706
55. Llado L, Virgili J, Figueras J, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000;88:50-7 (Pubitemid 30027678)
56. Kim HC, Kim AY, Han JK, et al. Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images. Radiology 2002;225:773-80 (Pubitemid 35387116)
57. Lim JH, Choi D, Kim SH, et al. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol 2002;179:67-73 (Pubitemid 34694813)
58. Wasser K, Giebel F, Fischbach R, et al. Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (Spherex): personal investigations and review of the literature. Radiologe 2005;45:633-43 (Pubitemid 41151576)
59. Civalleri D, Pector JC, Hakansson L, et al. Treatment of patients with irresectable liver metastases from colorectal cancer by chemo-occlusion with degradable starch microspheres. Br J Surg 1994;81:1338-41 (Pubitemid 24275162)
60. Taguchi T. Chemo-occlusion for the treatment of liver cancer. A new technique using degradable starch microspheres. Clin Pharmacokinet 1994;26:275-91 (Pubitemid 24116206)
61. Persson BG, Jeppsson B, Ekberg H, et al. Repeated dearterialization of hepatic tumors with an implantable occluder. Cancer 1990;66:1139-46 (Pubitemid 20310652)
62. Leichman CG, Jacobson JR, Modiano M, et al. Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: a southwest oncology group pilot trial. Cancer 1999;86:775-81 (Pubitemid 29399916)
63. Sanz-Altamira PM, Spence LD, Huberman MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum 1997;40:770-5 (Pubitemid 27295046)
64. Voigt W, Behrmann C, Schlueter A, et al. A new chemoembolization protocol in refractory liver metastasis of colorectal cancer-a feasibility study. Onkologie 2002;25:158-64 (Pubitemid 34507665)
65. Lang EK, Brown CL Jr. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993;189:417-22 (Pubitemid 23321421)
66. Fiorentini G, Aliberti C, Benea G, et al. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology 2008;55:2077-82
67. Aliberti C, Tilli M, Benea G, et al. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res 2006;26:3793-5 (Pubitemid 44701461)
68. Martin RC, Howard J, Tomalty D, et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010;33:960-6
69. Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 2007;21:1085-91
70. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011;18:192-8
71. Brennan MJ, Talley RW, Drake EH, et al. 5-fluoruracil treatment of liver metastases by continuous hepatic artery infusion via cournand catheter: results and suitability for intensive postsurgical adjuvant chemotherapy. Ann Surg 1963;158:405-19
72. Sullivan RD, Norcross JW, Watkins E. Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion. N Engl J Med 1964;270:321-7
73. Koea JB, Kemeny N. Hepatic artery infusion chemotherapy for metastatic colorectal carcinoma. Semin Surg Oncol 2000;19:125-34
74. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002;29:119-25 (Pubitemid 34297282)
75. Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008;15:219-26
76. Barone RM, Byfield JE, Goldfarb PB, et al. Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases. Cancer 1982;50:850-62 (Pubitemid 12047115)
77. Callahan MK, Kemeny NE. Implanted hepatic arterial infusion pumps. Cancer J 2010;16:142-9
78. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459-65 (Pubitemid 17149758)
79. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-93 (Pubitemid 18056182)
80. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989;7:1646-54 (Pubitemid 19272834)
81. Martin JK Jr, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990;125:1022-7 (Pubitemid 20249340)
82. Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990;8:1885-93 (Pubitemid 20382353)
83. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-18
84. Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-60 (Pubitemid 24334681)
85. Lorenz M, Muller HH, Schramm H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenousinfusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;18:243-54 (Pubitemid 30056411)
86. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomized trial. Lancet 2003;361:368-73 (Pubitemid 36164968)
87. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-403 (Pubitemid 46622004)
88. Fiorentini G, Cantore M, Rossi S, et al. Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. In Vivo 2006;20:707-9
89. Mocellin S, Pilati P, Lise M, et al. Meta-analysis of hepatic arterialinfusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007;25:5649-54
90. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009:CD007823
91. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996;88:252-8
92. Hildebrandt B, Pech M, Nicolaou A, et al. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach. BMC Cancer 2007;7:69
93. Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005;201:57-65 (Pubitemid 40840564)
94. Herrmann KA, Waggershauser T, Sittek H, et al. Liver intraarterial chemotherapy: use of the femoral artery for percutaneous implantation of catheter-port systems. Radiology 2000;215:294-9 (Pubitemid 30190544)
95. Tanaka T, Arai Y, Inaba Y, et al. Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 2003;14:63-8 (Pubitemid 36134075)
96. Ricke J, Hildebrandt B, Miersch A, et al. Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. J Vasc Interv Radiol 2004;15:825-33 (Pubitemid 39063222)
97. Michels NA. Newer anatomy of the liver and its variant blood supply and collateral circulation. Am J Surg 1966;112:337-47
98. Holen KD, Saltz LB. New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. Lancet Oncol 2001;2:290-7 (Pubitemid 33591567)
99. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553-60 (Pubitemid 46196586)
100. Kemeny N, Capanu M, D'Angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 2009;20:1236-41
101. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005;23:4888-96 (Pubitemid 46223994)
102. Seki H, Ozaki T, Shiina M. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. Cardiovasc Intervent Radiol 2009;32:679-86
103. Kern W, Beckert B, Lang N, et al. Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response. Anticancer Res 2000;20:4973-5 (Pubitemid 32319062)
104. Del Freo A, Fiorentini G, Sanguinetti F, et al. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer. In Vivo 2006;20:743-6 (Pubitemid 46061613)
105. Neyns B, Van Nieuwenhove Y, Aerts M, et al. Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. Anticancer Res 2006;26:611-19 (Pubitemid 43206025)
106. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le. Cancer J Clin Oncol 2005;23:4881-7 (Pubitemid 46223993)
107. Goere D, Deshaies I, De Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010;251:686-91
108. Pozzo C, Barone C, Kemeny NE. Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treat Rev 2008;34:293-301
109. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47
110. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predictlong-term survival. Ann Surg 2004;240:644-57
111. Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009;27:3465-71
112. Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007;14:3188-94 (Pubitemid 47594272)
113. Muratore A, Polastri R, Bouzari H, et al. Repeat hepatectomy for colorectal liver metastases: a worthwhile operation? J Surg Oncol 2001;76:127-32
114. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906-11
115. Asahara T, Kikkawa M, Okajima M, et al. Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepatogastroenterology 1998;45:805-11 (Pubitemid 28321062)
116. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002;20:1499-505 (Pubitemid 34260528)
117. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48 (Pubitemid 30035952)
118. Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001;48:1685-91 (Pubitemid 34003504)
119. Rudroff C, Altendorf-Hoffmann A, Stangl R, et al. Prospective randomized trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 1999;384:243-9 (Pubitemid 29309067)
120. Ito H, Are C, Gonen M, et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008;247:994-1002 (Pubitemid 351770420)
121. Vahrmeijer AL, Van Der Eb MM, van Dierendonck JH, et al. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Semin Surg Oncol 1998;14:262-8 (Pubitemid 28146519)
122. Alexander HR Jr, Bartlett DL, Libutti SK, et al. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol 2009;16:1852-9
123. Rothbarth J, Pijl ME, Vahrmeijer AL, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 2003;90:1391-7 (Pubitemid 37421675)
124. Alexander HR Jr, Bartlett DL, Libutti SK, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998;16:1479-89 (Pubitemid 28175769)
125. Farma JM, Pingpank JF, Alexander HR. Isolated hepatic perfusion: treating unresectable liver metastases. Adv Exp Med Biol 2006;574:1-16
126. Bartlett DL, Libutti SK, Figg WD, et al. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001;129:176-87
127. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 2000;82:1539-46 (Pubitemid 30204359)
128. Eggermont AM, van IJken MG, van Etten B, et al. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology 2000;47:776-81 (Pubitemid 30417294)
129. Rothbarth J, Pijl ME, Tollenaar RA, et al. An experimental minimally invasive perfusion technique for the treatment of liver metastases. Eur J Surg Oncol 2003;29:757-63 (Pubitemid 37483950)
130. van Etten B, Brunstein F, van IJken MG, et al. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. Ann Surg Oncol 2004;11:598-605 (Pubitemid 40486717)
131. Verhoef C, de Wilt JH, Brunstein F, et al. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. Ann Surg Oncol 2008;15:1367-74